Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | TSHR | P16473 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA4 | P22748 | 1/20 | 0.53 |
| ▸ | CA6 | P23280 | 1/20 | 0.53 |
| ▸ | CA7 | P43166 | 1/20 | 0.53 |
| ▸ | TPMT | P51580 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.53 |
| ▸ | PARP1 | P09874 | 2/20 | 0.52 |
| ▸ | PARP10 | Q53GL7 | 2/20 | 0.52 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.52 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.52 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29415167 | 0.86 | MAPK1 (0.77) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL335681 | 0.86 | MAPK1 (0.77) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL29161873 | 0.85 | MEN1 (0.53) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL8424777 | 0.85 | MAPK1 (0.60) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL5154533 | 0.84 | MAPK1 (0.74) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL2601961 | 0.83 | CYP1A2 (0.81) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| Hydrochloric Acid SCHEMBL10554176 | 0.83 | MAPK1 (0.58) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL801748 | 0.82 | LMNA (0.57) | TSHRCYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL503429 | 0.82 | CA12 (0.71) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31406172 | 0.82 | CA12 (0.71) | MAPK1TSHRCYP1A2CYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 85 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115991661-B | Preparation method of high-purity non-neridone key intermediate | 浙江科聚生物医药有限公司 | 2024-10-01 | — | — | CN | claimed |
| EP-4143187-B1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-ALPHA AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2024-05-08 | — | — | EP | claimed |
| CN-115991661-A | Preparation method of high-purity non-neridone key intermediate | 浙江科聚生物医药有限公司 | 2023-04-21 | — | — | CN | claimed |
| CN-115485275-A | Compounds and compositions that inhibit HIF 2-alpha activity and methods of use thereof | 诺华股份有限公司 | 2022-12-16 | — | — | CN | claimed |
| CN-115368272-A | Preparation method of 4-cyano-2-methoxybenzaldehyde | 汉瑞药业(荆门)有限公司 | 2022-11-22 | — | — | CN | claimed |
| CN-107721869-A | A kind of synthetic method of the cyanobenzaldehyde of 2 methoxyl group 4 | 上海雅本化学有限公司 | 2018-02-23 | — | — | CN | claimed |
| US-8288552-B2 | Dihydropyridone amidesas P2X7 modulators | ROCHE PALO ALTO LLC (US) | 2012-10-16 | — | — | US | claimed |
| EP-4698175-A1 | LYSINE ACETYLTRANSFERASE 6A (KAT6A) INHIBITOR, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-02-25 | — | — | EP | disclosed |
| US-12448365-B2 | Aryl aminopyrimidines as dual MerTK and TYRO3 inhibitors and methods thereof | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2025-10-21 | — | — | US | disclosed |
| CN-116157403-B | Morphology of treasiril and method for producing same | 海南先声再明医药股份有限公司 | 2025-04-25 | — | — | CN | disclosed |
| WO-2025081982-A1 | PREPARATION METHOD FOR FINERENONE KEY INTERMEDIATE | 山东诚创蓝海医药科技有限公司 | 2025-04-24 | — | — | WO | disclosed |
| CN-119859112-A | Preparation method of non-neridrone key intermediate | 山东诚创蓝海医药科技有限公司 | 2025-04-22 | — | — | CN | disclosed |
| CN-119823124-A | Compounds for targeted degradation of BRD9 | C4医药公司 | 2025-04-15 | — | — | CN | disclosed |
| US-6946472-B2 | Polycyclic compounds exhibiting anti-tumor activities | HOFFMAN-LA ROCHE INC. (US) | 2005-09-20 | — | — | US | disclosed |
| EP-1436293-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-14 | — | — | EP | disclosed |
| US-6680326-B2 | ANTITUMOR AGENTS; ANTICANCER AGENTS | HOFFMANN-LA ROCHE INC. | 2004-01-20 | — | — | US | disclosed |
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | F.HOFFMANN-LA ROCHE AG (CH) | 2003-12-11 | — | — | US | disclosed |
| WO-2003093265-A1 | DIMERIC POLYCYCLIC COMPOUNDS FOR THE TREATMENT OF TUMORS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-11-13 | — | — | WO | disclosed |
| US-20030073691-A1 | Polycyclic compounds | HOFFMANN-LA ROCHE INC. | 2003-04-17 | — | — | US | disclosed |
| WO-2003031444-A1 | POLYCYCLIC COMPOUNDS HAVING ANTI-TUMOR ACTIVITY | F. HOFFMANN-LA ROCHE AG (CH) | 2003-04-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073691-A1 | Polycyclic compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, PKD1 | MAPK1 2584/4885TSHR 2557/4885CYP1A2 1989/4885 |
| US-12448365-B2 | Aryl aminopyrimidines as dual MerTK and TYRO3 inhibitors and methods thereof | MERTK, TYRO3, MATK | MAPK1 763/4885TSHR 2254/4885CYP1A2 3562/4885 |
| US-20030229098-A1 | Polycyclic compounds exhibiting anti-tumor activities | RB1, CCNA1, ACIN1 | MAPK1 1957/4885TSHR 2461/4885CYP1A2 2249/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.